Alx Oncology Holdings (ALXO) Cash & Equivalents (2019 - 2026)

Alx Oncology Holdings (ALXO) has 8 years of Cash & Equivalents data on file, last reported at $32.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 56.61% year-over-year to $32.3 million; the trailing twelve-month figure through Mar 2026 stood at $32.3 million (up 56.61% YoY), and the FY2025 full-year result was $16.4 million, down 6.8% from the prior year.
• Cash & Equivalents advanced to $32.3 million in Q1 2026, from $16.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $159.1 million in Q1 2022 to a low of $14.0 million in Q1 2024.
• A 5-year average of $37.8 million and a median of $22.4 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents slumped 87.26% in 2022 and jumped 56.61% in 2026, its largest moves.
• Tracing ALXO's Cash & Equivalents over 5 years: stood at $48.8 million in 2022, then tumbled by 54.11% to $22.4 million in 2023, then slipped by 21.6% to $17.6 million in 2024, then decreased by 6.8% to $16.4 million in 2025, then jumped by 97.18% to $32.3 million in 2026.
• Business Quant data shows ALXO's Cash & Equivalents at $32.3 million in Q1 2026, $16.4 million in Q4 2025, and $23.4 million in Q3 2025.